Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$26.62
-3.3%
$29.28
$10.83
▼
$41.14
$3.54B-0.091.41 million shs1.51 million shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$10.19
+0.2%
$10.97
$6.39
▼
$26.95
$857.87M1.57986,535 shs987,179 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$44.89
-4.2%
$45.69
$14.78
▼
$62.32
$3.45B0.341.50 million shs747,595 shs
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$28.47
+0.8%
$30.19
$22.66
▼
$42.49
$3.49BN/A908,768 shs602,369 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-1.01%-10.97%+4.48%-28.70%+96.85%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-4.06%-10.55%+6.83%-33.96%+14.14%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-1.62%-8.50%+25.54%-21.11%+115.30%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-0.70%-5.90%+24.18%-31.63%+2,824,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$26.62
-3.3%
$29.28
$10.83
▼
$41.14
$3.54B-0.091.41 million shs1.51 million shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$10.19
+0.2%
$10.97
$6.39
▼
$26.95
$857.87M1.57986,535 shs987,179 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$44.89
-4.2%
$45.69
$14.78
▼
$62.32
$3.45B0.341.50 million shs747,595 shs
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$28.47
+0.8%
$30.19
$22.66
▼
$42.49
$3.49BN/A908,768 shs602,369 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-1.01%-10.97%+4.48%-28.70%+96.85%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-4.06%-10.55%+6.83%-33.96%+14.14%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-1.62%-8.50%+25.54%-21.11%+115.30%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-0.70%-5.90%+24.18%-31.63%+2,824,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$43.7164.22% Upside
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.88
Moderate Buy$32.83222.21% Upside
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.75
Moderate Buy$75.4468.07% Upside
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
2.78
Moderate Buy$40.8043.31% Upside

Current Analyst Ratings Breakdown

Latest CRVS, AMLX, PBLS, and ELVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
UpgradeSell (D) ➝ Sell (D+)
11/11/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
UpgradeStrong Sell ➝ Hold
11/10/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Boost Price TargetOutperform$38.00 ➝ $39.00
11/9/2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
Initiated CoverageBuy$39.00
11/6/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Reiterated RatingBuy$78.00
11/5/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Set Price Target$45.00
11/5/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Initiated CoverageStrong-Buy
11/3/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Reiterated RatingSell (D-)
11/2/2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
DowngradeSell (D+) ➝ Sell (D)
10/29/2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Set Price Target$27.00
10/26/2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Reiterated RatingSell (D-)
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M39.17N/AN/A$5.86 per share4.54
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/A$0.13 per share80.23$2.47 per shareN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$11.92 per shareN/A
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/A$8.13 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.44N/AN/AN/AN/A-41.54%-38.91%N/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$15.28M-$0.71N/AN/AN/AN/A-34.98%-32.67%N/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$103.69M-$1.71N/AN/AN/AN/A-16.91%-16.52%N/A
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-$145.89M-$2.13N/AN/AN/AN/A-73.69%-25.40%N/A

Latest CRVS, AMLX, PBLS, and ELVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-$0.40-$0.36+$0.04-$0.36N/A$2.11 million
11/5/2026Q3 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3810-$0.38+$0.0010-$0.38$0.06 millionN/A
11/5/2026Q3 2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.1924-$0.22-$0.0276-$0.22N/AN/A
11/5/2026Q3 2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.4479-$0.36+$0.0879-$0.36N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
26.81
26.81
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
13.38
13.38
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
45.95
45.95
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A
12.88
12.88

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
136128.56 million114.55 millionOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3784.35 million67.74 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
6573.60 million71.39 millionOptionable
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
145123.53 millionN/AOptionable

Recent News About These Companies

HC Wainwright Has Negative Estimate for PBLS FY2026 Earnings
Parabilis Medicines Q3 Loss Narrows
Parabilis Medicines: Q3 earnings snapshot
Transcript : Parabilis Medicines, Inc. - Special Call
Brokers Offer Predictions for PBLS Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$26.62 -0.90 (-3.27%)
Closing price 04:00 PM Eastern
Extended Trading
$27.36 +0.74 (+2.78%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$10.19 +0.02 (+0.20%)
Closing price 04:00 PM Eastern
Extended Trading
$10.20 +0.01 (+0.10%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$44.89 -1.96 (-4.18%)
Closing price 04:00 PM Eastern
Extended Trading
$44.88 -0.01 (-0.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Parabilis Medicines stock logo

Parabilis Medicines NASDAQ:PBLS

$28.47 +0.22 (+0.78%)
As of 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.